Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
74.15
Nov 17 • 3:59 PM ET Dollar change-1.42 Percentage change(-1.88%)
Aftermarket Close
74.15
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
3.40B
Enterprise Value
4.39B
Income
4.00M
Sales
1.86B
Book/sh
40.84
Cash/sh
10.48
Employees
2900
IPO
May 08, 1950
P/E
852.30
Forward P/E
15.11
PEG
0.89
P/S
1.82
P/B
1.82
P/C
7.07
P/FCF
11.51
EV/EBITDA
12.43
EV/Sales
2.36
Quick Ratio
1.89
Current Ratio
2.96
Debt/Eq
0.80
LT Debt/Eq
0.78
Option/Short
Yes / Yes
EPS (ttm)
0.09
EPS next Y
4.91
EPS next Q
0.38
EPS this Y
27.65%
EPS next Y
16.17%
EPS next 5Y
16.91%
EPS past 3/5Y
-70.41% -52.65%
Sales past 3/5Y
-5.26% -2.47%
EPS Y/Y TTM
106.07%
Sales Y/Y TTM
2.08%
EPS Q/Q
-150.00%
Sales Q/Q
4.18%
Insider Own
1.29%
Insider Trans
0.00%
Inst Own
113.83%
Inst Trans
-3.70%
ROA
0.55%
ROE
1.33%
ROIC
0.12%
Gross Margin
27.48%
Oper. Margin
7.25%
Profit Margin
0.21%
SMA20
-0.79%
SMA50
3.04%
SMA200
14.89%
Trades
Shs Outstand
45.79M
Shs Float
45.20M
52W High
79.50 -6.73%
52W Low
48.00 54.48%
Volatility
2.47% 2.64%
ATR (14)
2.04
RSI (14)
49.86
Beta
0.36
Rel Volume
0.91
Avg Volume
639.49K
Volume
580,747
Perf Week
-3.46%
Perf Month
4.16%
Perf Quarter
2.32%
Perf Half Y
35.61%
Perf YTD
26.38%
Perf Year
49.50%
Perf 3Y
-3.58%
Perf 5Y
-30.66%
Perf 10Y
38.63%
Prev Close
75.57
Price
74.15
Change %
-1.88%
Consensus
Strong Buy
Avg. Price Target
$82.45
Implied Upside
+11.2%
Analysts12incl. previous ratings
Rating Distribution8 Buy · 4 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 06, 2026Upgrade
SSeaport Research Partners
Neutral → Buy$75+1.1%
Dec 15, 2025Upgrade
BMO logoBBMO Capital Markets
Market Perform → Outperform$71-4.2%
Sep 08, 2025Initiated
MS logoMMorgan Stanley
Equal-Weight$60-19.1%
May 01, 2025Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight
Mar 26, 2025Upgrade
JPM logoJJP Morgan
Neutral → Overweight$68 → $71-4.2%
Mar 05, 2025Downgrade
SSeaport Research Partners
Buy → Neutral
Aug 08, 2024Upgrade
JPM logoJJP Morgan
Underweight → Neutral$90 → $89+20.0%
Apr 11, 2024Upgrade
WFC logoWWells Fargo
Equal Weight → Overweight$100 → $112+51.0%
Mar 14, 2024Upgrade
JEF logoJJefferies
Hold → Buy$100 → $126+69.9%
Mar 01, 2024Initiated
WWolfe Research
Outperform$108+45.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MUSA OSAMA MSVP and CTOSep 21 '26Option Exercise69.0610,418719,46741,224Sep 23 04:30 PM
LAMPKIN ROBIN E.SVP, GC & SecretaryAug 11 '26Option Exercise74.581,806134,6916,825Aug 12 04:30 PM
MUSA OSAMA MSVP and CTOJul 29 '26Option Exercise57.961,26773,43530,806Jul 30 04:30 PM
Assis Alessandra FaccinSVP and GM, Life SciencesJul 27 '26Option Exercise66.383,215213,4129,099Jul 29 04:30 PM
MINICUCCI JAMES P.SVP and GM, Personal CareMay 08 '26Option Exercise55.014,310237,0938,567May 11 04:30 PM
Kulkarni Ashish KDirectorJan 21 '26Option Exercise0.002,11302,113Jan 22 04:30 PM
Ashland, Inc. is an additives and specialty ingredients company, which engages in the provision of architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical products. It operates through the following segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. The Life Sciences segment is involved in pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, diagnostic films, and fine chemicals. The Personal Care segment consists of biofunctionals, microbial protectants, skin care, sun care, oral care, hair care, and household solutions. The Specialty Additives segment focuses on rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive, and various industrial markets. The Intermediates segment refers to production of 1,4 butanediol and related derivatives, including n-methylpyrrolidone. The company was founded in 1924 and is headquartered in Wilmington, DE.
Chairman & CEOMr. Guillermo Novo
Senior VPMr. William C. Whitaker C.F.A.
Senior VP & CTODr. Osama M. Musa Ph.D.
Senior VP & GM of Personal CareMr. James P. Minicucci
Senior VP and GM of Life Sciences & IntermediatesMs. Alessandra Faccin Assis